Short answer
Zimmer Biomet (ZBH) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2.0B (up 9.7% year over year) with net income of $231M.
Q3 2025 key financials · XBRL
- Revenue
- $2.0B
- +9.7% YoY · −3.7% QoQ
- Net income
- $231M
- −7.3% YoY · +51.0% QoQ
- Operating margin
- 17.6%
- EPS (diluted)
- $1.16
- −5.7% YoY · +50.6% QoQ
Source: XBRL data from the Zimmer Biomet (ZBH) Q3 2025 10-Q on SEC EDGAR. USD.
Zimmer Biomet Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.001B Q3 2025, up 9.7% vs $1.824B Q3 2024; Nine months $5.988B, up 5.9% vs $5.655B 2024
- Operating profit margin Q3 17.6% vs 15.3% YoY; Nine months 15.8% vs 15.9% YoY (slight decrease)
- Best segment: Americas Q3 operating margin 51.6% vs 53.3% YoY, worst: EMEA 29.2% vs 32.9% YoY
- Cash $1.293B as of Sept 30, 2025; operating cash flow $1.180B nine months, financing cash inflow $1.223B due to senior notes issuance
- Management expects full year 2025 revenue growth 6.7%-7.7%, earnings decline due to acquisition costs, inflation, tariffs, higher interest, tax rate increase
Risk Factors
- No new or changed risk factors since 2024 Form 10-K disclosed in this 10-Q
- Continued exposure to product liability and regulatory compliance risks from medical device industry regulations
- Ongoing market risk from global healthcare budget constraints and competitive orthopedic device market
- Operational risk from supply chain disruptions impacting product availability and manufacturing timelines
- Financial risk includes potential impact from foreign currency fluctuation on international sales and earnings
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zimmer Biomet quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.